Blog
Filter blogs by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
Diabesity: Overlapping pathophysiology informs multi-indication treatment
As recognition of the overlap between obesity and diabetes has grown, so have efforts to develop treatments that can treat the two conditions in tandem.
-
Site Training for Clinical Trial Success
Training site staff on clinical trial protocols takes time and money, and poor training modules can lead to low compliance or staff that is technically trained, but have missed the learning objectives. Effective training using rich and varied content, leveraging highly engaging methodology and comprehension checks will provide learners with confidence and retention long after the training is completed. Learn more about what you need to reduce risk, increase compliance and enhance quality with a comprehensive training solution.
-
Beyond awareness: Driving progress on the Rare Disease journey
ICON employees share their experience with Rare Diseases.
-
Rare disease trials require effective participation support strategies to succeed
ICON is leading the way in rare disease clinical research having supported 778 rare disease clinical trials in the past five years. Every day, thousands of colleagues at ICON work tirelessly to support the success of rare disease clinical research – because patients can’t wait.
-
Strategies for de-risking rare disease programmes during research and development
Difficulties in research and development for rare disease therapeutics have been compounded by a historically challenging market for biotechs. ICON experts share how biotechs can maximise funding for rare disease therapeutic development in our blog.
-
Insights from the 2024 ISCR Annual Conference: India’s evolving clinical research arena
ICON participated in the 17th annual Indian Society for Clinical Research (ISCR) conference on the 1-3 February in Hyderabad, India. ICON experts shared insights on topics of special interest including clinical data management and biostatistics and statistical programming, among others.
-
-420x250.jpg?crop=yes&w=210&h=209&itok=QktejwFj "(10708-PV-Affiliate-Model-Whitepaper)-420x250.jpg")
Ensuring safety and compliance: The essentials of outsourcing pharmacovigilance
In this blog, we delve into the rationale behind outsourcing pharmacovigilance activities at the affiliate level and explore the essential requirements for appointing local persons for pharmacovigilance (LPPVs).
-
Looking forward: The most significant 2024 US healthcare trends - Part 5 of 5
When discussing the 5 biggest challenges that await the healthcare industry in 2024, US politics is a key issue. America is clearly divided on many issues, including those involving government spending, healthcare reimbursements, and treatment coverage issues.
-
Looking forward: The most significant 2024 US healthcare trends—Part 4 of 5
Given that some of the overall physical- and mental-health indicators show negative progress even while healthcare costs are rising, it begs the question: What is the reason for the backslide?
-
Looking forward: The most significant 2024 US healthcare trends—Part 3 of 5
Physical- and mental-health measure declines are 2 factors likely to impact the healthcare industry as they move forward in 2024 and beyond. Not surprisingly, concerns over rising healthcare costs and how to best control them continue to dominate in significance.
-
Looking forward: The most significant 2024 US healthcare trends - Part 2 of 5
In addition to physical health indicators, mental health declines also serve as a measure of the serious health concerns to the healthcare industry in the United States. These changes likely impact drug manufacturers directly and indirectly through market needs, opportunities, and resource allocations related to the development and marketing of both existing and prospective treatments.
-
Looking forward: The most significant 2024 US healthcare trends - Part 1 of 5
2024 may well be the most challenging year yet for the US healthcare industry. Our research reveals 5 overarching trends likely to have the strongest impact on the industry and improving the health of Americans for the months and years ahead.
-
How pharma can use social determinant of health to address health equity
The majority of our disease risk is social and environmental, not genetic, meaning the social determinants of health are a key piece of the puzzle. Effectively leveraging SDoH data can help close the gap in health equity and reveal new insights to guide pharma brand growth.
-
How data intelligence tools are enhancing signal detection methods
Advancements in intelligence tools such as ICON’s Signet help overcome challenges with data volume, complexity and completeness to accurately and rapidly detect safety signals to ensure patient safety throughout the drug’s lifecycle.
-
Trialling abroad: How sponsors, ethics committees and regulators can improve patient outcomes in cross-border trials
Patients’ need for novel investigational treatments for life-impacting diseases in the absence of available treatment options drives an ongoing debate on how sponsors, ethics committees and regulatory bodies can work together to overcome both logistical and regulatory barriers.
-
Continuing the fight against AMR with new tools for diagnosis and treatment
The employment of antimicrobials to fight previously devastating microbial diseases, such as tuberculosis, meningitis and pneumonia, has been credited as being one of the most transformative medical achievements of the 20th century.
-
The impact of pediatric medical trauma in clinical trials
Up to 80% of children and their families experience pediatric medical trauma after medical interactions of significant illnesses. Read the insights shared by a panel of Pediatric Medical Trauma Working Group members to learn how patient-centric pediatric trials can help mitigate the potential for medical trauma and its life-long implications.
-
Navigating CTIS: Setting up clinical trials under EU CTR
The EU CTR Nº 536/2014 came into force on 31 January 2022, repealing the Clinical Trials Directive and improving the harmonisation of clinical trials regulation throughout the EU and European Economic Area (EEA).
-
Digital therapeutics considerations for CNS
This blog explores DTx in CNS clinical trials: regulatory landscape, data management, endpoints, payer coverage, and future trends.
-
Expanding CAR T-cell Therapy into solid tumours
In this blog, learn more about a range of approaches that researchers are taking to improve the efficacy and safety of CAR T-cell therapies in solid tumours.